



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 72588

Title: New Insights in Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05125057

Position: Peer Reviewer

Academic degree: MSc, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: Croatia

Author's Country/Territory: United States

Manuscript submission date: 2021-10-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-10-21 06:02

Reviewer performed review: 2021-10-28 05:52

Review time: 6 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="checkbox"/>] Anonymous [<input type="checkbox"/>] Onymous Conflicts-of-Interest: [<input type="checkbox"/>] Yes [<input checked="" type="checkbox"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The manuscript entitled 'New insights in Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms' provides an overview of gastroenteropancreatic neuroendocrine neoplasms by the site of origin, histological classification, Ki-67 proliferation index, and genetic background. The authors also presented the clinical picture of different types of NENs accompanied by imaging and their diagnosis and treatment options. The manuscript is very detailed but also systematically written, and there is no need to add anything.



PEER-REVIEW REPORT

Name of journal: *World Journal of Gastroenterology*

Manuscript NO: 72588

Title: New Insights in Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms.

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02978155

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor, Professor

Reviewer's Country/Territory: Italy

Author's Country/Territory: United States

Manuscript submission date: 2021-10-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-10-22 16:31

Reviewer performed review: 2021-11-02 16:15

Review time: 10 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input checked="" type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
---------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

The present review, titled “New insights in Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms” aimed at reviewing the main clinical and biological characteristics which determine the management of neuroendocrine neoplasms. Although this issue is very interesting and actual, the study has important limitations - First of all, the review is not innovative and does not add anything new to what is already known in the literature - Moreover, it lacks citations of important papers that represent milestones for NEN therapy and management, such as some randomized studies in this area, as the pivotal trials PROMID, CLARINET FORTE and some RADIANT trials (i.e. Arnold R, et al. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. *J Clin Oncol.* 2009 or Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med.* 2014. Or Pavel M, et al. 1162MO Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results. *Ann Oncol.* 2020. or Yao JC, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study) as well as important reviews (i.e. Pavel M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2020;31(7):844–60. Or Mohammed Dawod et al. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. *Curr Treat Options Oncol.* 2021 Jun 29;22(8):73. or



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Massironi S, et al. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Scand J Gastroenterol. 2016;51(5):513-23.) - The author correctly used the most recent definition of neuroendocrine tumors namely “neuroendocrine neoplasms” (NEN), reserving the term “tumor” for well-differentiated forms only (G1 according to last WHO edition). But, throughout the manuscript, they create a sort of confusion in the use of both NEN and NET; please check and be more clear. - English language needs to be reviewed and checked by an English native speaker. Only as an example, on page 3-Introduction, the authors wrote “. Majority (> 95%) of the GEP-NENs are sporadic, but some (~5%) could be part of a syndromic presentations”: The indefinite article a may not be required with the plural noun presentations. Also the formatting was not correct (i.e. spacing, citations, abbreviates, etc).